Article Text

PDF
AB0462 The Risk of Cancer in Systemic Lupus Erythematosus in Chinese Population: A Single-Center Experience
  1. J. Qi,
  2. P. Zhang,
  3. Z. Hu,
  4. Z. Chen,
  5. J. Gu
  1. Department of Rheumatology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

Abstract

Background It was reported that incidence rate of malignant tumor in general population was 0.24% in China in 2010. Cyclophosphamide is widely used in the treatment of systemic lupus erythematosus. Long term use of CTX may lead to increase the risk of tumor. However, whether the Cyclophosphamide risk of cancer will increase is not clear.

Objectives To investigate the risk of cancer in systemic lupus erythematosus patients.

Methods We studied retrospectively systemic lupus erythematosus patients coexist with malignancies hospitalized in the Third Affiliated hospital of Sun Yat-sen University from 1999 to 2015. The study included 2530 systemic lupus erythematosus patients.

Results The ratio of systemic lupus erythematosus with malignancies was 0.24% in these patients (6/2530). Compared to general population, no increase in tumor incidence was found in systemic lupus erythematosus. The onset age of SLE was 47±17.8years,and the age of the patients with cancer were 50.7±14.9years.There were 6 solid tumor in our study, including three thyroid carcinoma, one nasopharyngeal carcinoma, one nerve glioma, and one meningioma.

Conclusions The incidence of tumor in SLE patients was similar to the general populations.

  1. Chen, W.; Zheng, R.; Zhang, S.; Zhao, P.; Zeng, H.; Zou, X., Report of cancer incidence and mortality in China, 2010. Annals of translational medicine 2014, 2 (7), 61.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.